PRESS RELEASE
News
-
-
-
PRESS RELEASE
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment -
-
PRESS RELEASE
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations -
-
-
-
PRESS RELEASE
AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science presents financial information for the year 2023, including clinical development updates and intellectual property strengthening. Consolidated operating loss decreased by 15.7% compared to 2022
